Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsShares IssuedShares RepurchasedShort-Term Debt repayments
Ratios

Ani Pharmaceuticals (ANIP) Short-Term Debt repayments (2020 - 2025)

Historic Short-Term Debt repayments for Ani Pharmaceuticals (ANIP) over the last 6 years, with Q3 2025 value amounting to $2.0 million.

  • Ani Pharmaceuticals' Short-Term Debt repayments changed N/A to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $297.1 million, marking a year-over-year increase of 3971240.0%. This contributed to the annual value of $292.5 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Short-Term Debt repayments is $2.0 million.
  • Ani Pharmaceuticals' 5-year Short-Term Debt repayments high stood at $291.0 million for Q4 2024, and its period low was -$2.2 million during Q4 2022.
  • In the last 5 years, Ani Pharmaceuticals' Short-Term Debt repayments had a median value of $2.0 million in 2025 and averaged $33.1 million.
  • Its Short-Term Debt repayments has fluctuated over the past 5 years, first tumbled by 10117.12% in 2022, then skyrocketed by 1303333.33% in 2024.
  • Over the past 5 years, Ani Pharmaceuticals' Short-Term Debt repayments (Quarter) stood at $192.1 million in 2021, then tumbled by 101.17% to -$2.2 million in 2022, then changed by 0.0% to -$2.2 million in 2023, then surged by 13033.33% to $291.0 million in 2024, then crashed by 99.3% to $2.0 million in 2025.
  • Its Short-Term Debt repayments was $2.0 million in Q3 2025, compared to $2.0 million in Q2 2025 and $2.0 million in Q1 2025.